Australia's CSL eyes best day in 25 years on strong FY outlook

CSL

18/08/2026 02:20

** Shares of CSL CSL.AX rise as much as 18.1% to A$159.01, hitting their highest level since February 12
** Stock set for best intraday trading session since June 2001
** Biotech giant reports better-than-expected full-year underlying earnings and forecasts strong growth in 2027 on the back of its core plasma division
** CSL posts underlying NPAT attributable of $3.14 bln on a constant currency basis, topping Visible Alpha consensus estimate of $3.08 bln
** Plasma therapies unit CSL Behring expected to post mid-single-digit revenue growth in FY 2027 
** Co unveils A$1.1 bln ($781.66 mln) share buyback programme
** With much of the earnings damage already reflected in a share price near multi-year lows, the buyback and a more constructive outlook for Behring are strengthening view that the worst may be behind CSL - Hebe Chen, market analyst at Vantage Markets
** Day's moves cut stock's YTD losses to 9.2%

($1 = 1.4073 Australian dollars)

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))